Biodexa Pharmaceuticals Plc (BDRX) Form 424B3 — Sep 15, 2026
Biodexa Pharmaceuticals entered a warrant inducement agreement under which an accredited holder is exercising all of its Series M, N and O warrants — an aggregate of 2,204,218 ADSs — at a reduced exercise price of $1.05, delivering the company approximately $2.3 million in gross proceeds before fees and expenses. In exchange for exercising at the reduced price, the holder receives new unregistered Series P warrants to purchase 4,408,436 ADSs (200% coverage) at $1.05, immediately exercisable with a five-year term. Maxim Group LLC acted as warrant inducement agent for an 8.0% cash fee of gross proceeds.
Key figures
- Gross Proceeds
- 2300000
- Offering Price
- 1.05
- Shares Offered
- 2204218
- New warrant ads
- 4408436
- Warrant term years
- 5
- Ordinary shares per ads
- 50
- Prior closing price usd
- 1.12
- Maxim fee percent of gross
- 8
- Series m warrants exercised
- 282952
- Series n warrants exercised
- 701754
- Series o warrants exercised
- 1219512
- New warrant coverage percent
- 200
- Resale registration deadline days
- 15
- Registration effectiveness deadline days
- 45
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.